Cardiac Science (CSCX) Reports Large Q3 Loss; Issues Mixed Guidance for Q4

November 9, 2009 4:35 PM EST

Cardiac Science (NASDAQ: CSCX) reports a Q3 loss of $2.85 vs. the analyst estimate of ($0.12) - may not be comparable. Revenue for the quarter was $38.9 million, which compares to the estimate of $37.40 million.

(The Company also recorded a charge of $18.5 million for an AED field product update and a non-cash charge of $44.0 million to increase its valuation allowance against deferred income tax assets. Including these charges, the Company reported a net loss for the quarter of $66.5 million, or $2.85 per share)

The Company expects revenue for the fourth quarter of 2009 to be in a range between $39.0 million and $41.0 million. (consensus is $39.20M)

The Company expects to report a net loss for the quarter in a range between $4.0 and $5.0 million, or between $0.17 and $0.21 per share. (consensus is a loss of $0.05)

Related Categories

Earnings
Guidance

Stocks Mentioned

Add Your Comment

Name

Subject

Body

Verification can't see the text?
click here to refresh the image.
what's this?